Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G/A | 2019-02-14 | MAVERICK CAPITAL LTD | Impax Laboratories, LLC | 0 | 0.0% | EDGAR |
SC 13G/A | 2019-02-12 | WELLINGTON MANAGEMENT GROUP LLP | Impax Laboratories, LLC | 0 | 0.0% | EDGAR |
SC 13G/A | 2018-04-10 | VANGUARD GROUP INC | IMPAX LABORATORIES INC | 7,443,386 | 10.1% | EDGAR |
SC 13G/A | 2018-02-14 | Hound Partners, LLC | IMPAX LABORATORIES INC | 0 | 0.0% | EDGAR |
SC 13G | 2018-02-12 | MAVERICK CAPITAL LTD | IMPAX LABORATORIES INC | 7,327,798 | 9.9% | EDGAR |
SC 13G/A | 2018-02-09 | VANGUARD GROUP INC | IMPAX LABORATORIES INC | 7,036,174 | 9.5% | EDGAR |
SC 13G | 2018-02-08 | WELLINGTON MANAGEMENT GROUP LLP | IMPAX LABORATORIES INC | 4,136,625 | 5.6% | EDGAR |
SC 13G/A | 2018-02-06 | Invesco Ltd. | IMPAX LABORATORIES INC | 1,893,054 | 2.6% | EDGAR |
SC 13G/A | 2018-01-19 | BlackRock Inc. | IMPAX LABORATORIES INC | 9,837,282 | 13.3% | EDGAR |
SC 13G | 2017-08-31 | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | IMPAX LABORATORIES INC | 3,854,995 | 5.2% | EDGAR |
SC 13G/A | 2017-02-14 | Hound Partners, LLC | IMPAX LABORATORIES INC | 4,436,376 | 6.0% | EDGAR |
SC 13G/A | 2017-02-13 | ORBIMED ADVISORS LLC | IMPAX LABORATORIES INC | 0 | 0.0% | EDGAR |
SC 13G/A | 2017-02-10 | VANGUARD GROUP INC | IMPAX LABORATORIES INC | 5,974,630 | 8.1% | EDGAR |
SC 13G/A | 2017-02-08 | Invesco Ltd. | IMPAX LABORATORIES INC | 4,045,960 | 5.5% | EDGAR |
SC 13G/A | 2017-01-12 | BlackRock Inc. | IMPAX LABORATORIES INC | 8,416,071 | 11.4% | EDGAR |
SC 13G/A | 2016-02-12 | ORBIMED ADVISORS LLC | IMPAX LABORATORIES INC | 2,653,500 | 3.8% | EDGAR |
SC 13G/A | 2016-02-11 | VANGUARD GROUP INC | IMPAX LABORATORIES INC | 5,176,732 | 7.3% | EDGAR |
SC 13G | 2016-02-10 | Invesco Ltd. | IMPAX LABORATORIES INC | 3,749,785 | 5.3% | EDGAR |
SC 13G | 2016-02-05 | FRANKLIN RESOURCES INC | IMPAX LABORATORIES INC | 4,052,698 | 5.6% | EDGAR |
SC 13G/A | 2016-01-08 | BlackRock Inc. | IMPAX LABORATORIES INC | 7,547,477 | 10.7% | EDGAR |